



(51) International Patent Classification:
C12Q 1/6886 (2018.01)

(21) International Application Number:
PCT/US2023/075498

(22) International Filing Date:
29 September 2023 (29.09.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/377,808 30 September 2022 (30.09.2022) US

(71) Applicant: **LIQUID BIOPSY RESEARCH LLC**
[KN/KN]; Hunkins Waterfront Plaza, P.O. Box 556 Main
Street, Charlestown, 00109-7000 (KN).

(72) Inventors; and

(71) Applicants: **MODLIN, Irvin Mark** [US/US]; 11 Tulip
Tree Lane, Woodbridge, Connecticut 06525 (US); **KIDD,
Mark** [US/US]; 1a Ira Street, New Haven, Connecti-
cut 06512 (US); **DROZDOV, Ignat** [GB/GB]; 19 Great
William Street, Stratford Upon Avon Warwickshire CV37
6RY (GB).

(74) Agent: **PAVAO, Matthew** et al.; Cooley LLP, 1299 Penn-
sylvania Ave., Suite 700, Washington, District of Columbia
20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: METHODS FOR NEUROENDOCRINE CANCER DETECTION IN SALIVA




FIG. 1

(57) Abstract: The present inventions are directed to methods for detecting a neuroendocrine cancer in saliva, methods for determining the completeness of surgery, methods for determining whether a neuroendocrine cancer is stable or progressive, and methods for evaluating the response to a neuroendocrine cancer therapy.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*